Hengrui’s Lutetium [177Lu] Oxy-Octreotide Gains Clinical Clearance in China
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical clearance from the National Medical...
Drug
Changchun BCHT Gains NMPA Approval for Herpes Zoster Vaccine
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced receiving marketing approval from the...
Jemincare’s Avatrombopag Market Filing Accepted for Review by China’s CDE
China-based Jiangxi Jemincare Group has announced that its market filing for avatrombopag maleate (20mg) has...
Ascletis Receives FDA Approval for Phase IIa Trial of ASC10 in RSV Infection
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving approval from the US FDA to...
Sirnaomics Accelerates STP705 Development After Positive Skin Cancer Trial Results
Sirnaomics Ltd (HKG: 2257) is advancing the clinical development of STP705 following positive results from...
Betta Pharmaceuticals Gains FDA Approval for Clinical Trial of BPI-460372
China’s Betta Pharmaceuticals (SHE: 300558) has announced receiving clinical trial approval from the US FDA...
Kelun’s SKB264 Receives Breakthrough Therapy Designation for Lung Cancer
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody-drug conjugate (ADC) SKB264,...
Hengrui’s Camrelizumab-Apatinib Combo Approved for Liver Cancer in China
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...
Yiling Pharmaceutical’s G201-Na Accepted for Review by China’s NMPA for Prostate Cancer
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...
Zhaoke Ophthalmology’s Cyclosporine A Eye Gel Nears Market Approval in China
Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...
Sciwind Biosciences Initiates Phase III Trial for Ecnoglutide in Type 2 Diabetes
Hangzhou-based Sciwind Biosciences Co., Ltd has announced the first subject dosing in a Phase III...
Beijing HSA Sets Price for Hainan Simcere’s COVID-19 Therapy SIM0417
Beijing’s municipal Healthcare Security Administration (HSA) bureau has released details of the initial quote and...
Qilu Pharmaceutical’s Biosimilar Lucentis Accepted for Review by China’s CDE
China-based Qilu Pharmaceutical has announced that its market approval filing for a biosimilar version of...
RemeGen’s Telitacicept Gains FDA Approval for Phase III Study in Myasthenia Gravis
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced receiving approval from the US...
Luye Pharma Gains CDE Approval for Goserelin Acetate Microspheres Clinical Study
China-based Luye Pharma Group (HKG: 2186) has announced receiving approval from the Center for Drug...
CARsgen and Roche Partner on Clinical Study for Gastric Cancer Treatment
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a clinical cooperation...
Haisco’s Prostate Cancer Drug HSK38008 and DPP-4 Inhibitor HSK7653 Accepted for Review
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the clinical trial filing for...
HealZen Therapeutics Gains NMPA Approval for HZ-A-018 Clinical Study in Autoimmune Diseases
Hangzhou-based HealZen Therapeutics has announced receiving approval from the National Medical Products Administration (NMPA) to...
Betta Pharmaceuticals’ BPI-D0316 Accepted for Review by CDE for First-Line NSCLC
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that another market approval filing for...
Jiangsu Alpha Biopharma’s Zorifertinib NDA Accepted for Review by CDE
China-based Jiangsu Alpha Biopharma Ltd has announced that the New Drug Application (NDA) for its...